Form 4: Corcept Therapeutics Executive Gary Robb Reports Changes in Beneficial Ownership

Gary Robb, Chief Business Officer of Corcept Therapeutics, reports changes in beneficial ownership of company stock, including stock grants, transfers, and holdings in custodial accounts.

Summary

• Gary Robb, the Chief Business Officer of Corcept Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock on June 24, 2024.
• The reported transactions include the disposition of 2,650 shares of common stock at $0.00, likely related to a grant or award.
• A transfer of 1,000 shares from a custodial account to the child's personal account is also reported.
• Robb also reported the acquisition of 550 shares each across four custodial accounts for his child, all at a price of $0.00.
• Following these transactions, Robb directly owns 26,291 shares and indirectly owns shares through custodial accounts.
• The direct holdings include shares underlying unvested restricted stock awards granted on various dates in 2023 and 2024, which vest on the one-year anniversary of the grant date.

Sentiment

Score: 5

Explanation: This Form 4 filing is a routine disclosure of stock transactions by a company executive and doesn't inherently convey positive or negative sentiment. It simply reflects changes in beneficial ownership.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the stock ownership of a key executive.
• The transactions themselves may have a negligible impact on the company's operations or financial performance.

Key Dates